Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.69 |
| ▸ | PPARG | P37231 | 13/20 | 0.59 |
| ▸ | RXRA | P19793 | 8/20 | 0.59 |
| ▸ | RXRB | P28702 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 5/20 | 0.59 |
| ▸ | RXRG | P48443 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | PTGES | O14684 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380949 | 0.84 | PPARA (0.67) | PPARAPPARGRXRARXRBPPARD | |
| Pirinixil SCHEMBL8015979 | 0.84 | PPARA (0.62) | PPARAPPARGRXRARXRBPPARD | |
| SCHEMBL10997557 | 0.83 | PPARA (0.48) | PPARAPPARGRXRARXRBPPARD | |
| SCHEMBL4433116 | 0.79 | PPARA (0.57) | PPARAPPARGRXRARXRBPPARD | |
| Acetic Acid SCHEMBL3773388 | 0.78 | PPARA (0.61) | PPARAPPARGRXRARXRBPPARD | |
| SCHEMBL15062964 | 0.77 | PPARA (0.56) | PPARAPPARGRXRARXRBPPARD | |
| SCHEMBL8015983 | 0.76 | PPARA (0.57) | PPARAPPARGRXRARXRBPPARD | |
| SCHEMBL10997703 | 0.76 | PPARA (0.58) | PPARAPPARGRXRARXRBPPARD | |
| Aronixil SCHEMBL2732727 | 0.75 | PPARA (0.64) | PPARAPPARGRXRARXRBPPARD | |
| Pirinixic Acid SCHEMBL293161 | 0.74 | PPARA (1.00) | PPARAPPARGRXRARXRBPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) | 2021-08-12 | — | — | US | claimed |
| EP-3841097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | Biomedical Research Foundation of the Academy of Athens (GR) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (BRFAA) (GR) | 2020-02-27 | — | — | WO | claimed |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2019-05-14 | — | — | US | claimed |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2018-07-26 | — | — | US | claimed |
| EP-3319965-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | Biomedical Research Foundation of the Academy of Athens (GR) | 2018-05-16 | — | — | EP | claimed |
| WO-2017005919-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2017-01-12 | — | — | WO | claimed |
| WO-2015104292-A2 | COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2015-07-16 | — | — | WO | claimed |
| US-7897326-B2 | Peroxisome-proliferator activated receptor-alpha agonists for organ preservation | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-03-01 | — | — | US | claimed |
| WO-2007106912-A2 | PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR-ALPHA AGONISTS FOR ORGAN PRESERVATION | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-09-20 | — | — | WO | claimed |
| US-20070218451-A1 | PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR-ALPHA AGONISTS FOR ORGAN PRESERVATION | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-09-20 | — | — | US | claimed |
| US-RE37770-E1 | SUCH AS LINOLEIC ACID, OLEIC ACID, 5,8,11,14-EICOSATETRAYNOIC ACID, 4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYL)THIOACETIC ACID, CLOFIBRATE, AND GEMFIBROZIL; USEFUL FOR TREATING DISORDERS OF EPIDERMAL DIFFERENTIATION AND PROLIFERATION. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-06-25 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | disclosed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | disclosed |
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) | 2021-08-12 | — | — | US | disclosed |
| US-6071955-A | TREATING TERRESTRIAL MAMMALIAN SUBJECT SUFFERING FROM A CONDITIONS OF ACNE AND ACNEIFORM CONDITIONS BY ADMINISTERING 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID METHYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | disclosed |
| US-6060515-A | TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1998032444-A1 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | PIK3R3, PIK3CA, PIK3C2A | PPARA 3064/4885PPARG 1288/4885RXRA 4165/4885 |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BRCA1, VHL, TSG101 | PPARA 1247/4885PPARG 693/4885RXRA 1180/4885 |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BRCA1, VHL, CYP27A1 | PPARA 796/4885PPARG 535/4885RXRA 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.